UBS Group’s Direxion mRNA ETF MSGR Stock Holding History

UBS Group’s Portfolio MSGR Stock Details MSGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-170	Closed	-$2.27K	–	10375
2023 Q1	$2.27K	Buy	+170	New	+$2.47K	﹤0.01%	8539
2022 Q4	–	Sell	-26,810	Closed	-$363K	–	11514
2022 Q3	$363K	Buy	26,810 +753	+3%	+$11.3K	﹤0.01%	4611
2022 Q2	$353K	Buy	26,057 +1,057	+4%	+$15.3K	﹤0.01%	4533
2022 Q1	$444K	Hold	25,000	–	–	﹤0.01%	4775
2021 Q4	$594K	Buy	+25,000	New	+$601K	﹤0.01%	4835

UBS Group's MSGR Position: Q2 2023 in Review

UBS Group sold out of Direxion mRNA ETF (MSGR) in Q2 2023, closing a stake of 170 shares — an estimated $2.27K sold.

UBS Group first reported a position in MSGR in Q4 2021 and held it in 5 quarters. The position peaked at $594K in Q4 2021. 0 funds tracked by Wall St. Rank hold MSGR as of Q2 2023.

UBS Group reported no remaining Direxion mRNA ETF position as of Q2 2023 after selling out during the quarter.
UBS Group sold 170 Direxion mRNA ETF shares in Q2 2023, an estimated $2.27K.
UBS Group first reported a position in Direxion mRNA ETF in Q4 2021 and held it in 5 quarters.
UBS Group's Direxion mRNA ETF position peaked at $594K in Q4 2021.
0 funds tracked by Wall St. Rank held Direxion mRNA ETF as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.